Myotonic Dystrophy Type 1 or Steinert's disease - PubMed (original) (raw)
Review
Myotonic Dystrophy Type 1 or Steinert's disease
Vincenzo Romeo. Adv Exp Med Biol. 2012.
Abstract
Myotonic Dystrophy Type 1 (DM1) is the most common worldwide autosomal dominant muscular dystrophy due to polynucleotide [CTG]( n ) triplet expansion located on the 3'UTR of chromosome 19q13.3. A toxic gain-of-function of abnormally stored RNA in the nuclei of affected cells is assumed to be responsible for several clinical features of the disease. It plays a basic role in deregulating RNA binding protein levels and in several mRNA splicing processes of several genes, thus leading to the multisystemic features typical of DM1. In DM1, the musculoskeletal apparatus, heart, brain, eye, endocrine, respiratory and gastroenteric systems are involved with variable levels of severity. DM1 onset can be congenital, juvenile, adult or late. DM1 can be diagnosed on the grounds of clinical presentation (distal muscular atrophy and weakness, grip and percussion myotonia, ptosis, hatchet face, slurred speech, rhinolalia), EMG myotonic pattern, EKG (such as AV-blocks) or routine blood test abnormalities (such as increased CK values or hypogamma-globulinemia) and history of cataract. Its confirmation can come by DNA analysis. At present, only symptomatic therapy is possible and is addressed at correcting hormonal and glycemic balance, removing cataract, preventing respiratory failure and, above all, major cardiac disturbances. Efficacious therapies targeted at the pathogenic mechanism of DM1 are not yet available, while studies that seek to block toxic RNA intranuclear storage with specific molecules are still ongoing.
Similar articles
- Myotonic dystrophy: clinical and molecular parallels between myotonic dystrophy type 1 and type 2.
Ranum LP, Day JW. Ranum LP, et al. Curr Neurol Neurosci Rep. 2002 Sep;2(5):465-70. doi: 10.1007/s11910-002-0074-6. Curr Neurol Neurosci Rep. 2002. PMID: 12169228 Review. - Myotonic dystrophy type 1 (DM1): a triplet repeat expansion disorder.
Kumar A, Agarwal S, Agarwal D, Phadke SR. Kumar A, et al. Gene. 2013 Jun 15;522(2):226-30. doi: 10.1016/j.gene.2013.03.059. Epub 2013 Apr 6. Gene. 2013. PMID: 23570879 - RNA pathogenesis of the myotonic dystrophies.
Day JW, Ranum LP. Day JW, et al. Neuromuscul Disord. 2005 Jan;15(1):5-16. doi: 10.1016/j.nmd.2004.09.012. Epub 2004 Nov 26. Neuromuscul Disord. 2005. PMID: 15639115 Review. - Clinical and molecular aspects of the myotonic dystrophies: a review.
Machuca-Tzili L, Brook D, Hilton-Jones D. Machuca-Tzili L, et al. Muscle Nerve. 2005 Jul;32(1):1-18. doi: 10.1002/mus.20301. Muscle Nerve. 2005. PMID: 15770660 Review. - [From gene to disease; altered RNA processing as a cause of myotonic dystrophy type 1].
de Die-Smulders CE, Faber CG, Smeets HJ. de Die-Smulders CE, et al. Ned Tijdschr Geneeskd. 2005 Sep 10;149(37):2043-6. Ned Tijdschr Geneeskd. 2005. PMID: 16184945 Review. Dutch.
Cited by
- Clinical characteristics of 37 Chinese patients with myotonic dystrophy Type 1.
Lu H, Li Y, Sadowsky M, Da Y. Lu H, et al. Brain Circ. 2016 Apr-Jun;2(2):95-98. doi: 10.4103/2394-8108.186282. Epub 2016 Jul 13. Brain Circ. 2016. PMID: 30276279 Free PMC article. - Fragile hearts: new insights into translational control in cardiac muscle.
Zarnescu DC, Gregorio CC. Zarnescu DC, et al. Trends Cardiovasc Med. 2013 Nov;23(8):275-81. doi: 10.1016/j.tcm.2013.03.003. Epub 2013 Apr 10. Trends Cardiovasc Med. 2013. PMID: 23582851 Free PMC article. Review. - Functional and histopathological identification of the respiratory failure in a DMSXL transgenic mouse model of myotonic dystrophy.
Panaite PA, Kuntzer T, Gourdon G, Lobrinus JA, Barakat-Walter I. Panaite PA, et al. Dis Model Mech. 2013 May;6(3):622-31. doi: 10.1242/dmm.010512. Epub 2012 Nov 23. Dis Model Mech. 2013. PMID: 23180777 Free PMC article. - Therapeutic Genome Editing for Myotonic Dystrophy Type 1 Using CRISPR/Cas9.
Wang Y, Hao L, Wang H, Santostefano K, Thapa A, Cleary J, Li H, Guo X, Terada N, Ashizawa T, Xia G. Wang Y, et al. Mol Ther. 2018 Nov 7;26(11):2617-2630. doi: 10.1016/j.ymthe.2018.09.003. Epub 2018 Sep 11. Mol Ther. 2018. PMID: 30274788 Free PMC article. - Can long-term thiamine treatment improve the clinical outcomes of myotonic dystrophy type 1?
Costantini A, Trevi E, Pala MI, Fancellu R. Costantini A, et al. Neural Regen Res. 2016 Sep;11(9):1487-1491. doi: 10.4103/1673-5374.191225. Neural Regen Res. 2016. PMID: 27857755 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials